Agena Bioscience Granted EUA for High-Throughput, Low-Cost SARS-CoV-2 Panel
The Pharma Data
OCTOBER 27, 2020
.” With the panel’s authorization, Agena also aims to alleviate material shortages, enabling laboratories to accelerate testing without concerns about instrument or reagent availability. “Agena proactively sourced and secured materials to provide uninterrupted product availability to our customers.
52 
Let's personalize your content